Most investors have never heard of Fuso Chemical Industries (TSE:4368). Almost every advanced chip made in the world — by TSMC, Samsung, Intel, anyone — has passed through a process that depends on it.
A Company With Two Unrelated World #1 Businesses
Fuso Chemical’s business splits into two pieces that have nothing to do with each other:
- Malic acid and fruit acids (food and beverage additives): roughly 50% global market share
- Ultra-high-purity colloidal silica (semiconductor polishing material): over 90% global market share
The second business is what matters here. Colloidal silica is the primary abrasive in CMP (chemical mechanical polishing/planarization) slurry — the material used to flatten a wafer’s surface after each layer of circuitry is built. Modern advanced logic chips have 10-15+ metal layers, and each layer requires its own planarization step. CMP isn’t a one-time process per chip; it repeats dozens of times across the manufacturing flow. As chips get more layers — driven by AI accelerators, advanced packaging, 3D NAND — slurry consumption scales with chip complexity, not just chip volume.
This is a structural demand driver, not a cyclical one tied to a single product cycle.
The News: A Government Subsidy, Not an Operational Surprise
On June 17, 2026, Fuso Chemical disclosed a JPY 3.7bn subsidy under Japan’s “Supply Chain Countermeasures Domestic Investment Promotion Program,” tied to capacity expansion at its Kyoto facility. The subsidy will be booked as extraordinary income, lifting interim net profit 33.1% to JPY 10.4bn. Full-year net profit guidance rises 15.7% to JPY 19.2bn.
Operating profit and ordinary income for the interim period are unchanged — this is a one-time policy benefit layered on top of an already-growing core business, not a sign of accelerating operations. Investors should not extrapolate the 33% jump into future quarters.
The subsidy sits inside a much larger plan: a JPY 40bn investment in Kyoto capacity announced in March 2026, with production starting in February 2029. The subsidy covers roughly 9% of that total.
The Stock Has Already Run
| Year | Close |
|---|---|
| 2024 | ¥1,188 |
| 2025 | ¥2,123 |
| 2026 (YTD high) | ¥4,740 |
From the 2024 close to the 2026 high, the stock is up roughly 4x, driven by the broader AI/semiconductor capex cycle re-rating materials suppliers across the chain. Current metrics: PER 21x, PBR 2.97x, ROE 12.9%, equity ratio 77%, dividend yield 0.85%, payout ratio around 28%.
The low payout ratio signals a reinvestment-first capital allocation policy — this is a growth holding, not an income one. The shareholder benefit program (hotel discount vouchers, regional gourmet gift points) is a nice touch but not the reason to own this.
Government Backing Reduces One Risk, Not All of Them
Classifying CMP slurry as economic-security-relevant infrastructure and subsidizing its expansion reduces capital risk for Fuso Chemical specifically — the company isn’t funding the full ¥40bn alone, and the subsidy is a signal that further government support could follow. That lowers the probability that the business itself disappears.
It says nothing about where the stock price goes from here. “The business is durable” and “the stock is undervalued” are different claims, and the second one is harder to support at 21x forward earnings after a 4x run.
The Timing Trap
A natural instinct is to wait for the Kyoto plant to start production in February 2029, see the resulting revenue increase, and buy then. This is usually the wrong sequencing for capacity-expansion stories.
March 2026: Investment announced → market re-rates immediately (PER already at 21x)
2026–2028: Construction phase → capex and depreciation precede revenue
February 2029: Plant comes online → revenue actually rises
Markets tend to price in capacity expansion well ahead of the revenue showing up. By the time the new plant is actually shipping product in 2029, the increase may already be reflected in the valuation built up over the prior three years — a classic “sell the news” setup. The period with the most asymmetric opportunity is usually the construction phase itself, when interim order strength or additional policy support can move the stock incrementally, not the eventual ribbon-cutting.
What Could Go Wrong
- Competitive erosion: Merck, Evonik, and others are investing in ultra-high-purity colloidal silica production. A 90%+ share is a target, not a permanent fixture.
- Technology substitution: Over a 10-20 year horizon, alternative planarization chemistries could reduce reliance on colloidal silica specifically — a low-probability but non-zero tail risk.
- Semiconductor capex cyclicality: Slurry consumption tracks wafer starts more than capex itself, which smooths some — but not all — of the industry’s boom-bust pattern.
- Valuation compression: Even if the business keeps growing, a 21x-PER, 3x-PBR stock has limited room for multiple expansion; further gains likely require earnings growth to do the work, not re-rating.
Bottom Line
The business is close to un-killable in any near-term sense — it sits at the center of a structurally growing, government-backed, high-barrier niche. The stock, however, has already absorbed most of that story. New money here is a bet on continued earnings delivery through 2029, not a bet on discovering an overlooked monopoly.
Source: Original filing (TDnet) | 日本語版
Disclaimer | This article is for informational purposes only and does not constitute investment advice.